Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015.

Alexandra Thomas | Anthony Rhoads | Elizabeth Pinkerton | Mary C Schroeder | Kristin M Conway | William G Hundley | Lacey R McNally | Jacob Oleson | Charles F Lynch | Paul A Romitti
JNCI cancer spectrum | 2019

Although recent findings suggest that de novo stage IV breast cancer is increasing in premenopausal women in the United States, contemporary incidence and survival data are lacking for stage I-III cancer.

Pubmed ID: 31392297

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCBDD CDC HHS, United States
    Id: U01 DD001223
  • Agency: NCI NIH HHS, United States
    Id: HHSN261201300020I
  • Agency: NCI NIH HHS, United States
    Id: P30 CA086862
  • Agency: NCBDD CDC HHS, United States
    Id: U01 DD001035
  • Agency: ACL HHS, United States
    Id: U01DD001223

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Surveillance Epidemiology and End Results (tool)

RRID:SCR_006902

SEER collects cancer incidence data from population-based cancer registries covering approximately 47.9 percent of the U.S. population. The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment, and they follow up with patients for vital status.There are two data products available: SEER Research and SEER Research Plus. This was motivated because of concerns about the increasing risk of re-identifiability of individuals. The Research Plus databases require more rigorous process for access that includes user authentication through Institutional Account or multiple-step request process for Non-Institutional users.

View all literature mentions